Androgen deprivation causes epithelial-mesenchymal transition in the prostate: Implications for androgen- deprivation therapy

Cancer Research

Volumn 72, Issue 2, 2012, Pages 527-536

  Sun, Yuting ^a   Wang, Bu Er ^a   Leong, Kevin G ^a   Yue, Peng ^a   Li, Li ^a   Jhunjhunwala, Suchit ^a   Chen, Darrell ^a   Seo, Kyounghee ^a   Modrusan, Zora ^a   Gao, Wei Qiang ^a,b   Settleman, Jeffrey ^a   Johnson, Leisa ^a  

^a GENENTECH INC   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ATAXIN 1; CADHERIN; CADHERIN 11; CD133 ANTIGEN; DOCETAXEL; FIBRONECTIN; FIBRONECTIN 1; HERMES ANTIGEN; LEFT RIGHT DETERMINATION FACTOR; LIN PROTEIN; NERVE CELL ADHESION MOLECULE; PROTEIN; SMAD3 PROTEIN; STEM CELL FACTOR RECEPTOR; TESTOSTERONE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST1; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

AGE; ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CASTRATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EXPLANT; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION;

ANDROGENS; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MALE; MICE; MICE, SCID; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; NEOPLASTIC STEM CELLS; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862908058     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3004     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96. (Pubitemid 351521864)
2. Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res 2009;15:3251-5.
3. Sharifi N, Kawasaki BT, Hurt EM, Farrar WL. Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy. Cancer Biol Ther 2006;5:901-6.
4. Damber JE, Aus G. Prostate cancer. Lancet 2008;371:1710-21. (Pubitemid 351671887)
5. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-8.
6. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.
7. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010;29: 4741-51.
8. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15. (Pubitemid 351636299)
9. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009;11:1487-95.
10. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006;66:944-50. (Pubitemid 43165962)
11. Sayan AE, Griffiths TR, Pal R, Browne GJ, Ruddick A, Yagci T, et al. SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc Natl Acad Sci U S A 2009;106:14884-9.
12. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009;138:645-59.
13. Gumireddy K, Li A, Gimotty PA, Klein-Szanto AJ, Showe LC, Katsaros D, et al. KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat Cell Biol 2009; 11:1297-304.
14. Xie D, Gore C, Liu J, Pong RC, Mason R, Hao G, et al. Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci U S A 2010;107:2485-90.
15. Saini S, Majid S, Yamamura S, Tabatabai ZL, Suh SO, Shahryari V, et al. Regulatory role of miR-203 in prostate cancer progression and metastasis. Clin Cancer Res 2010;17:5287-98.
16. Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 2010;16:286-94.
17. Abbas AR, Wolslegel K, Seshasayee D, Modrusan Z, Clark HF. Deconvolution of blood microarray data identifies cellular activation patterns in systemic lupus erythematosus. PLoS One 2009;4:e6098.
18. Leong KG, Wang BE, Johnson L, Gao WQ. Generation of a prostate from a single adult stem cell. Nature 2008;456:804-8.
19. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989;24: 148-54. (Pubitemid 19163397)
20. Sun Y, Ge Y, Drnevich J, Zhao Y, Band M, Chen J.Mammalian target of rapamycin regulates miRNA-1 and follistatin in skeletal myogenesis. J Cell Biol 2010;189:1157-69.
21. Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP, Witte ON. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci U S A 2008;105:20882-7.
22. Leong KG, Gao WQ. The Notch pathway in prostate development and cancer. Differentiation 2008;76:699-716. (Pubitemid 352036647)
23. Wang XD, Wang BE, Soriano R, Zha J, Zhang Z, Modrusan Z, et al. Expression profiling of the mouse prostate after castration and hormone replacement: implication of H-cadherin in prostate tumorigenesis. Differentiation 2007;75:219-34. (Pubitemid 46426622)
24. Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, et al. LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate 2003;55:239-46. (Pubitemid 36618182)
25. Nusse R, Fuerer C, Ching W, Harnish K, Logan C, Zeng A, et al. Wnt signaling and stem cell control. Cold Spring Harb Symp Quant Biol 2008;73:59-66.
26. Tabibzadeh S, Hemmati-Brivanlou A. Lefty at the crossroads of "stemness" and differentiative events. Stem Cells 2006;24:1998-2006. (Pubitemid 44477124)
27. Best CJ, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, Gathright Y, et al. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 2005;11:6823-34. (Pubitemid 41428737)
28. Love HD, Booton SE, Boone BE, Breyer JP, Koyama T, Revelo MP, et al. Androgen regulated genes in human prostate xenografts in mice: relation to BPH and prostate cancer. PLoS One 2009;4:e8384.
29. Russell PJ, Kingsley EA. Human prostate cancer cell lines. Methods in molecular medicine 2003;81:21-39.
30. Myers RM, Stamatoyannopoulos J, Snyder M, Dunham I, Hardison RC, Bernstein BE, et al. Auser's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol 2011;9:e1001046.
31. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, et al. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med 2010;16:1414-20.
32. Jennbacken K, Tesan T, Wang W, Gustavsson H, Damber JE, Welen K. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Endocr Relat Cancer 2010; 18:469-79.
33. Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, et al. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J 2000;6:220-33.
34. Singh S, Sadacharan S, Su S, Belldegrun A, Persad S, Singh G. Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. Cancer Res 2003;63:2306-11. (Pubitemid 36538641)
35. Xu G, Wu J, Zhou L, Chen B, Sun Z, Zhao F, et al. Characterization of the small RNA transcriptomes of androgen dependent and independent prostate cancer cell line by deep sequencing. PLoS One 2010;5: e15519.
36. Zhu ML, Kyprianou N. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J 2010;24:769-79.
37. Schaeffer EM, Marchionni L, Huang Z, Simons B, Blackman A, Yu W, et al. Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene 2008;27:7180-91.
38. Spoelstra NS, Manning NG, Higashi Y, Darling D, Singh M, Shroyer KR, et al. The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Res 2006;66:3893-902.
39. Qiao L, Tasian GE, Zhang H, Cunha GR, Baskin L. ZEB1 is estrogen responsive in vitro in human foreskin cells and is over expressed in penile skin in patients with severe hypospadias. J Urol 2011; 185:1888-93.
40. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 2007;13: 7003-11. (Pubitemid 350276881)